HomeCompareFPMI vs SBUX

FPMI vs SBUX: Dividend Comparison 2026

FPMI yields 1000000.00% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FPMI wins by $4.7683925249533696e+36M in total portfolio value
10 years
FPMI
FPMI
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full FPMI calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — FPMI vs SBUX

📍 FPMI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFPMISBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FPMI + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FPMI pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FPMI
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, FPMI beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FPMI + SBUX for your $10,000?

FPMI: 50%SBUX: 50%
100% SBUX50/50100% FPMI
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

FPMI
No analyst data
Altman Z
-206.3
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FPMI buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFPMISBUX
Forward yield1000000.00%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$4.7683925249533696e+36M$157.5K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$65,840.13
Total dividends collected$4.7683311610149396e+36M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: FPMI vs SBUX ($10,000, DRIP)

YearFPMI PortfolioFPMI Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,107$407.21+$100.00MFPMI
2$934,786,450,701$934,679,439,252.34$12,512$626.87+$934786.44MFPMI
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,366$978.69+$8165787108.56MFPMI
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,929$1,557.50+$66665884190957.63MFPMI
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$20,658$2,543.80+$508662171058048128.00MFPMI
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$26,406$4,302.22+$3.62723524842849e+21MFPMI
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$35,877$7,622.00+$2.417368115915061e+25MFPMI
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$52,741$14,352.64+$1.5056740286145463e+29MFPMI
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$85,676$29,243.03+$8.764771002818475e+32MFPMI
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$157,513$65,840.13+$4.7683925249533696e+36MFPMI

FPMI vs SBUX: Complete Analysis 2026

FPMIStock

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Full FPMI Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this FPMI vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FPMI vs SCHDFPMI vs JEPIFPMI vs OFPMI vs KOFPMI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.